Welcome to our dedicated page for Intercure Ltd. SEC filings (Ticker: INCR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Locating cultivation metrics, GMP certifications, and insider crop yield forecasts inside Intercure’s filings can feel like parsing two industries at once—pharma and agriculture. That complexity leads many professionals to ask, “How do I track Intercure insider trading Form 4 transactions or decode an Intercure quarterly earnings report 10-Q filing without spending hours?”
Stock Titan solves that problem with AI-powered summaries that highlight what matters in each form. From Intercure annual report 10-K simplified sections that spotlight global distribution costs, to Intercure 8-K material events explained when a new export permit lands, every document is parsed in real time. Need governance details? Our engine tags the Intercure proxy statement executive compensation tables, and pushes alerts on Intercure executive stock transactions Form 4. For short-term catalysts, you’ll see Intercure Form 4 insider transactions real-time right beside cash-flow snapshots and segment-level revenue graphs.
Whether you’re comparing yields quarter-over-quarter or understanding Intercure SEC documents with AI, our platform offers complete coverage—10-K, 10-Q, 8-K, S-1, SC 13G, everything—updated the moment EDGAR posts. Use instant filters to jump to GMP compliance notes, scan Intercure earnings report filing analysis for margin trends, or set watchlists that ping you before market open. Finally, Intercure SEC filings explained simply means you spend minutes, not afternoons, turning regulatory text into confident decisions.
InterCure Ltd. (dba Canndoc) reported a potential credit and operational issue related to its service provider Bazelet. The company learned that the Bazelet group of companies, a leading producer of cannabis oil and a key provider of production, EU-GMP-certified export, and Israeli distribution services, has entered restructuring proceedings in an Israeli District Court, including a temporary stay of proceedings.
InterCure holds Bazelet-issued checks totaling approximately NIS 27 million that remain outstanding during this stay, creating exposure to possible non-payment. The company states it is monitoring court developments, intends to pursue legal actions to protect its rights and interests as directed by its board, and is evaluating collaboration with an additional packaging facility to secure alternative service capacity.
InterCure Ltd. reported that it will hold its Annual General Meeting of Shareholders on December 30, 2025 at 4:00 p.m. (Israel time) at the offices of its legal counsel in Tel Aviv, Israel. The company is providing shareholders with a Notice and Proxy Statement describing the proposals to be voted on and the procedures for voting in person or by proxy, together with a Proxy Card that enables holders of ordinary shares to vote without attending the meeting. These materials are furnished as exhibits to the report so shareholders can review the agenda and participate in the decision-making process for the company.
InterCure Ltd. furnished a Form 6-K announcing it issued a press release on November 3, 2025 titled “InterCure and Cannasoul Sign Strategic Investment and Collaboration Agreements to Advance Cannabis Science and Pharmaceutical Innovation.” The press release is attached as Exhibit 99.1.
The filing highlights a strategic investment and collaboration framework with Cannasoul, focused on advancing cannabis science and pharmaceutical innovation. Additional details are contained in the attached press release.
FAQ
What is the current stock price of Intercure Ltd. (INCR)?
What is the market cap of Intercure Ltd. (INCR)?
